Clinical trials
Completed Observational Carcinoma, Renal Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
185 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 8 |
| 2008 | 17 |
| 2009 | 11 |
| 2010 | 11 |
| 2011 | 13 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 7 |
| 2015 | 7 |
| 2016 | 16 |
| 2017 | 1 |
| 2018 | 12 |
| 2019 | 19 |
| 2020 | 9 |
| 2021 | 10 |
| 2022 | 8 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 185 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 30 |
| Bayer | 10 |
| Radboud University Medical Center | 8 |
| Bristol-Myers Squibb | 6 |
| GlaxoSmithKline | 6 |
| Ipsen | 6 |
| Spanish Oncology Genito-Urinary Group | 4 |
| University Medical Center Groningen | 4 |
| First Affiliated Hospital of Fujian Medical University | 3 |
| Hoffmann-La Roche | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Renal Cell | 185 |
| Kidney Neoplasms | 36 |
| Neoplasms | 12 |
| Urinary Bladder Neoplasms | 10 |
| Melanoma | 9 |
| Breast Neoplasms | 8 |
| Carcinoma | 8 |
| Carcinoma, Hepatocellular | 8 |
| Pancreatic Neoplasms | 8 |
| Lung Neoplasms | 7 |
Trials
Showing 1 to 25 of 185. Each trial links to its page on Pharma Observatory.
85 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.